From: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Best Overall Response
n = 13 (%)
Partial Response (confirmed)
1 (7.7)
Partial Response (unconfirmed)
Stable Disease
5 (38.5)
Progressive Disease
6 (46.2)
Objective Response Rate
7.7%
Disease Control Rate
46.2%